Posted by Michael Wonder on 06 Jan 2021
Farxiga granted priority review in the US for the treatment of patients with chronic kidney disease
6 January 2021 - Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type 2 diabetes mellitus.
AstraZeneca’s Farxiga (dapagliflozin) has been granted priority review in the US for the treatment of new or worsening chronic kidney disease in adults with and without type 2 diabetes mellitus.
